Cyclophosphamide and Iphosphamide against Lewis Lung Carcinoma: Evaluation of Toxic and Therapeutic Effects
Open Access
- 1 April 1979
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 65 (2) , 169-180
- https://doi.org/10.1177/030089167906500205
Abstract
In the present report, investigations have been carried out to evaluate toxic and therapeutic effects of cyclophosphamide vs its isomer iphosphamide. Cytostatic action of the 2 drugs was assayed on the murine Lewis lung carcinoma (3LL). It has been observed that iphosphamide is less toxic as compared to cyclophosphamide ; on the other hand, to reach the same therapeutic effectiveness on 3LL, an iphosphamide dose 1.6 - 2 times higher than that of its parent compound is necessary.
This publication has 6 references indexed in Scilit:
- Ifosfamide in the treatment of recurrent or disseminated lung cancerA phase II study of two dose schedulesCancer, 1978
- Surgical adjuvant chemotherapy of metastatic murine tumorsCancer, 1977
- REDUCTION OF IFOSFAMIDE TOXICITY USING DOSE FRACTIONATION1976
- Concepts for systemic treatment of micrometastasesCancer, 1975
- Accurate Identification of Experimental Pulmonary Metastases2JNCI Journal of the National Cancer Institute, 1966
- A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS1949